IDEXX Laboratories Q4 Adjusted PS $2.34 Beats $2.12 Estimate, Sales $901.60M Beat $891.25M Estimate
Portfolio Pulse from Benzinga Newsdesk
IDEXX Laboratories (NASDAQ:IDXX) reported Q4 adjusted earnings of $2.34 per share, surpassing the $2.12 estimate, and sales of $901.60M, exceeding the $891.25M estimate. This represents a 17% increase in earnings and an 8.81% increase in sales from the same period last year.
February 05, 2024 | 11:32 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
IDEXX Laboratories reported a significant beat on both earnings and sales estimates for Q4, with earnings per share at $2.34 and sales at $901.60M.
The positive earnings and sales beat by IDEXX Laboratories indicate strong financial health and operational efficiency, likely leading to increased investor confidence and a potential short-term uptick in IDXX stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100